Free Trial

Plexus Corp. (NASDAQ:PLXS) Shares Sold by Dimensional Fund Advisors LP

Plexus logo with Computer and Technology background

Dimensional Fund Advisors LP trimmed its position in shares of Plexus Corp. (NASDAQ:PLXS - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,545,061 shares of the technology company's stock after selling 89,788 shares during the quarter. Dimensional Fund Advisors LP owned approximately 5.71% of Plexus worth $241,773,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PLXS. TD Private Client Wealth LLC purchased a new position in shares of Plexus during the 4th quarter valued at approximately $28,000. R Squared Ltd purchased a new stake in Plexus in the 4th quarter worth $45,000. Nomura Asset Management Co. Ltd. increased its holdings in Plexus by 45.5% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 320 shares of the technology company's stock worth $50,000 after acquiring an additional 100 shares in the last quarter. USA Financial Formulas purchased a new stake in Plexus in the 4th quarter worth $56,000. Finally, Blue Trust Inc. increased its holdings in Plexus by 12.1% in the 4th quarter. Blue Trust Inc. now owns 776 shares of the technology company's stock worth $121,000 after acquiring an additional 84 shares in the last quarter. 94.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PLXS shares. Needham & Company LLC reissued a "buy" rating and issued a $162.00 price target (down previously from $172.00) on shares of Plexus in a report on Friday. Benchmark cut their price target on shares of Plexus from $170.00 to $160.00 and set a "buy" rating for the company in a report on Friday. Finally, Stifel Nicolaus set a $145.00 price target on shares of Plexus in a report on Thursday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $155.67.

View Our Latest Report on Plexus

Plexus Price Performance

PLXS traded up $1.45 on Friday, hitting $126.80. 142,114 shares of the company's stock were exchanged, compared to its average volume of 166,801. Plexus Corp. has a fifty-two week low of $99.79 and a fifty-two week high of $172.89. The company has a current ratio of 1.53, a quick ratio of 0.70 and a debt-to-equity ratio of 0.07. The firm has a 50-day moving average price of $125.74 and a 200-day moving average price of $144.27. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of 29.42 and a beta of 0.83.

Plexus (NASDAQ:PLXS - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The technology company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.59 by ($0.10). Plexus had a return on equity of 10.36% and a net margin of 3.03%. As a group, equities analysts anticipate that Plexus Corp. will post 5.9 earnings per share for the current year.

Insiders Place Their Bets

In other Plexus news, CFO Patrick John Jermain sold 3,361 shares of the business's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $144.57, for a total value of $485,899.77. Following the transaction, the chief financial officer now directly owns 20,745 shares in the company, valued at $2,999,104.65. The trade was a 13.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Angelo Michael Ninivaggi, Jr. sold 3,423 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $145.14, for a total transaction of $496,814.22. Following the sale, the chief accounting officer now owns 29,501 shares of the company's stock, valued at $4,281,775.14. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,958 shares of company stock valued at $2,551,930 in the last 90 days. 1.76% of the stock is owned by insiders.

About Plexus

(Free Report)

Plexus Corp. provides electronic manufacturing services in the United States and internationally. It offers design, develop, supply chain, new product introduction, and manufacturing solutions, as well as sustaining services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors.

Featured Stories

Institutional Ownership by Quarter for Plexus (NASDAQ:PLXS)

Should You Invest $1,000 in Plexus Right Now?

Before you consider Plexus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plexus wasn't on the list.

While Plexus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines